Plastic Packaging Standards: Grandfathering Exemption. Horacio Pappa, Ph.D. Director, General Chapters

Similar documents
Overview of USP Activities and How to Get Involved

Sample Sizes in Uniformity Measurements The Role of USP

Latest USP Initiatives: Monographs, General Chapters, and Compounding

PDA: A Global. Association. Proposed Revisions to USP <1207> STERILE PRODUCT -

Managing Your Environmental Isolates

STIMULI TO THE REVISION PROCESS

Challenges And Opportunities In Developing And Modernizing Public Standards For NF Monographs

Proposed New USP General Chapter: The Analytical Procedure Lifecycle 1220

PQRI/USP Workshop on Implementation Status of ICH Q3D Elemental Impurity Requirements

Growth Promotion Test Guide for Media Used in Sterility Tests

Paradigm Shift in Comparability Assessment:

USP/FDA OTC Drug Substances and Drug Products Workshop September 8-9, 2011 USP Headquarters Rockville, MD. Workshop Highlights and Recommendations

USP Perspective on Pharmaceutical Waters. Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 7, 2017

11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS. Siriphorn Laomanacharoen 21 December 2012

USP Priority Excipient Monograph Modernization Updates

MICROBIAL LIMIT TESTS FOR RAW MATERIALS AND NON-STERILE PRODUCTS REVIEW-DISCUSSIONS-INTERPRETATIONS

ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management

Critical Quality Attributes for Biotechnology Products: A Regulatory Perspective

Multiple stakeholders; one objective. Atypical Actives Industry Perspective. USP Excipients Stakeholder Forum November 29, 2017

Analytical Methods Development and Validation

Preservative Challenge Testing and Compendia: Efficient Efficacy

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon

History and Update of Chapters 797 and 800

Analysis of elemental impurities in drug products using the Thermo Scientific icap 7600 ICP-OES Duo

Overview of USP Efforts to Identify Naming Schemes for Tissues and Tissue-Based Products

QbD Concepts Applied to Qualification and Transfer of Analytical Methods

Extractables and leachables: An Introduction

Flexible and Pending Monographs

Metrics in Microbiology Monitoring Practices

Pharmacopoeial Reference Standards

Designing an effective cleaning procedure for medical devices through laboratory studies

Biowaiver Approaches for Generic Drug Products in the US: Case Studies

Sodium Hydroxide. Product Regulatory Data Sheet

Role of Industry in USP Monograph Modernization. ExcipientFest Americas 2015 APRIL 29, Agenda

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.

Capillary Electrophoresis Compendial Applications

PHARMACEUTICAL TESTING

Early Development Best Practices for Stability- Regulatory Perspective

Experience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014

Erin Patton, MS Senior Product Specialist Charles River Labs, Microbial Solutions

Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA

Compounding Aseptic Isolators (CAI) James T Wagner

Enhanced Mechanical Calibration of Dissolution Test Equipment

Derivation and Justification of Safety Thresholds

ICH Q12: Perspectives on Post-approval

How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.

Pharmaceutical Packaging Systems

Activities of the USP Microbiology Subcommittee of Revision During the Revision Cycle

Process Filtration From Pure to Sterile

Non-clinical Assessment Requirements

Validation of Sterilizing Grade Filters

REACH and RoHS updates for EU and Asia Pacific countries Mike McNally Antea Group

Workshop! Javad Jassbi Feb 2016

CANADA (HEALTH CANADA)

ERO Enterprise Compliance Auditor Manual & Handbook Florida Reliability Coordinating Council, Inc. Spring Workshop April 8-10, 2014

Latest Developments in USP Monographs and the Compounding of Sterile Radiopharmaceuticals. Jim Ponto, MS, RPh, BCNP

METHOD DEVELOPMENT AND APPLICATION TO STANDARD TEST METHODS AN ANAL YTICAL APPROACH TO STANDARD PERFORMANCE TESTING OF PSA TAPES

THE SOLVENTS / EMISSIONS OF VOLATILE ORGANIC COMPOUNDS (VOC) LEGISLATION

UNIVERSITY OF EXETER DISCIPLINARY PROCEDURE. Disciplinary Policy and Procedure

Global Biologics Regulatory Trends Challenges and Opportunities..

Advanced Concepts for Change Control of Analytical Procedures with ICH Q12 Coming

EDQM Conference. The European Pharmacopoeia Is it prepared for the future? Workshop 5. Workshop October 2010 Prague, Czech Republic

with an Example of for an HPLC Procedure

Guidance for Industry

Update on the revision of ISO/IEC 17025

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Process Filtration From Pure to Sterile

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Post market Surveillance ISO EU Medical Device Regulation

The Research Proposal - The Research on Measuring AEO MRA Effect - October, 2012

The purpose of this procedure is to define internal audit activities of PRI s administration of the Industry Managed Accreditation Programs.

Leachables & Extractables

HP Indigo for Food Flexible Packaging

Summary of Public Comments received on the Challenge substance Hydrazine (CAS ) Draft Screening Assessment Report for Batch 10

European Pharmacopoeia Reference Standards A Lodi, Head of the Laboratory Department, EDQM, Council of Europe

Chin Koerner Executive Director US Regulatory and Development Policy

Biopharmaceutical Method Transfer as part of the Quality System.

How to complete PPG s Raw Material Information Request (RMIR) Form

How to Identify Critical Quality Attributes and Critical Process Parameters

Complexity of Retention Samples Selection in non-traditional Bioequivalence studies

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.

Quantitation of amorphous content

Julie Roberts. Audit hot Topics and Regulatory Requirements

Reflection Paper. The Role of Product-specific Monographs for Biotherapeutic Products in Pharmacopoeias

Strategic Implantation of PAT : FDA Perspective

The Device Side of Combination Products

Requirements Analysis and Design Definition. Chapter Study Group Learning Materials

LEGAL REQUIREMENTS FOR STABILITY

Introduction and Key Concepts Study Group Session 1

The future clinical trial authorisation process: the new evaluation process

1 Analytical Validation within the Pharmaceutical Lifecycle

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

European Regulations for Medicines. Place and Role of the European Pharmacopoeia in Europe Ph. Eur. concept

PSM RMP CalARP Regulatory Framework Update & Implementation Strategies with Focus on Oil and Gas Facilities

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group

California Healthy Workplace Healthy Family Act of 2014

The Most Probable Number Method and Its Use in QC Microbiology

Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey

Transcription:

Plastic Packaging Standards: Grandfathering Exemption Horacio Pappa, Ph.D. Director, General Chapters

Overview: <661> Plastic Packaging Systems and their Materials of Construction General Notices and Requirements <659> Packaging and Storage Requirements <661> Plastic Packaging Systems and their Materials of Construction <661.1> Plastic Material of Construction - Identification - Biological Activity - Physico-chemical Tests - Extractable Metals - Plastic Additives <661.2> Plastic Packaging Systems for Pharmaceutical Use - Biological Activity - Physico-chemical Tests - Safety Assessment (Extractables/Leachables)

Revision Timeline PF 39 (5) Sep 2013 <661>, <661.1> and <661.2> PF 39 (6) Nov 2013 Stim Article Outlining Rationale for Revision PF 40 (5) Sep 2014 PF 42 (4) June 2016 2 Day Workshop Official: May 1, 2016 Applicable: May 1, 2017 via reference in <659> Total: 42 Months

Revision Impact 50 year old standard was revised Added new polymers Added new testing procedures and specifications Currently approved drug products that uses a plastic component in it s packaging system could be impacted.

Grandfather Currently Approved Products Scope: Alternatively, individual plastic materials of construction are deemed to be well characterized and appropriate for use if they are used in a packaging system that meets the requirements in 661.2 or if the packaging system has been deemed appropriate for pharmaceutical use by the appropriate regulatory authority. 5

PD EC Thinking on Grandfathering They considered removing the grandfathering provision from the chapters However, the concerns that led to including the grandfather language are still a point discussion Industry impact Currently approved products where packaging system can t meet new standard Material and component suppliers (market withdrawal) Timeline for removal What is a realistic timeline for the removal of the provision Communication plan Best way to communicate this change to effected stakeholders 6

Can we alleviate the uncertainty regarding the implementation? OPTION 1: Alternatively, individual plastic materials of construction are deemed to be well characterized and appropriate for use if they are used in a packaging system that meets the requirements in 661.2 or if the packaging system has been deemed appropriate for pharmaceutical use by the appropriate regulatory authority. ( Official unt il xxx) OPTION 2: Alternatively, individual plastic materials of construction are deemed to be well characterized and appropriate for use if they are used in a packaging system that meets the requirements in 661.2 For currently marketed articles, the implementation date for the requirements in this chapter will be XXX. 7

Delayed Implementation vs Grandfathering Delayed implementation is the preferred option. Several examples: <467> Organic Volatile Impurities and <467> Residual Solvents <61> Microbial Examination, <61> Microbial Enumeration and <62> Tests for Specified Microorganisms <231> to <232>/<233> Harmonization: <711>/<724>; <905> Grandfathering clause, not commonly used: <1226> Verification of compendial procedures: This chapter is not intended for retroactive application to already successfully established laboratory procedures. 8

Revision bulletin In accordance with section 7.05(c) of the Rules and Procedures of the Council of Experts, this is to provide notice that the Packaging and Distribution Expert Committee intends to revise the following General Chapters: <659> Packaging and Storage Requirements <661> Plastic Packaging Systems and Their Materials of Construction <661.1> Plastic Materials of Construction <661.2> Plastic Packaging Systems for Pharmaceutical Use 9

Revision bulletin The purpose of the revisions are: to provide a three-year period for implementation of the requirements specified in General Chapters <661.1> and <661.2>, to reinstate requirements previously expressed in General Chapter <661> during this three-year period; to enable early adoption of the requirements in General Chapters <661.1> and <661.2> at any time during the three-year period in lieu of meeting the reinstated <661> requirements; to remove the exemptions to General Chapters <661.1> and <661.2.> for previously approved packaging systems. 10

Revision bulletin 661.1 and 661.2 This chapter will become official on May 1, 2020. Early adoption of the requirements in this chapter and its companion chapter <661.2> are permitted by USP. When early adoption is not used, <661> will apply and must be met wherever <661.1> or <661.2> is referenced in the USP- NF. 11